6 Recommendations Regarding HTAs in the United States
A whitepaper was recently released by researchers at the USC Schaeffer Center and the Aspen Institute. The authors discuss half [...]
How Will the United States Address High Drug Prices?
American legislators are frustrated by high drug prices. In addition to financial distress from medication payments, some patients resort to [...]
Growing Support for HTA in Light of High Gene Therapy Costs
An independent review board, such as ICER, responsible for assessing appropriate costs for therapies and drugs has been discussed for [...]
ICER Releases Draft Evidence Report for Several Multiple Myeloma Therapies: Will These Drugs Prevent Relapse?
ICER has released a report on three therapies for multiple myeloma: belantamab mafodotin blmf from Blenrep™ and GlaxoSmithKline, idecabtagene vicleucel [...]
CBO Paper Details Future Impact of ICER
The Congressional Budget Office (CBO) put out a draft of a paper where it notes calculations regarding Medicare drug prices. [...]
How Should COVID-19 Vaccines Be Priced?
The US government has entered into contracts with several pharmaceutical companies to deliver COVID-19 vaccines. Although it is currently not [...]
Global HTA Comparison Finds 3 Top Organizations–Including ICER
Eight global HTA (health technology assessment) organizations were compared in a recent study. The leaders were NICE (UK), ICER (US), [...]
ICER Evidence Report for Inclisiran Released
Inclisiran by Novartis may be priced lower than other drugs targeting LDL cholesterol. Now that ICER has released its pricing [...]
What Will Happen to Novartis Cholesterol Drug?
Novartis drug inclisiran wasn’t reviewed on time by the FDA—largely because of COVID-19 travel restrictions. Now, the company seeks to [...]
